Vivalytic | SARS-CoV-2 Rapid 39 Minute Test

SARS-CoV-2 Rapid Test

SARS-CoV-2 Pooling Test

Vivalytic Test Menu

Download Vivalytic Brochure

Vivalytic | Viral Respiratory Infection Array

Posted on 28th July 2020 at 10:59 am.

Written by Martin Conway

Vivalytic | 10-Plex Viral Respiratory Infection Array

–

Detect 10 viral respiratory infections in 2 hours 30 minutes

Research Use Only

Download Flyer

Detecting SARS-CoV-2 (COVID-19)

Detection of up to 10 viral targets simultaneously from a single patient sample in 2.5 hours

Full molecular workflow consolidated into one small benchtop platform

Comprises sarbecovirus as a confirmatory target accurately diagnosing COVID-19

Target genes in line with WHO & CDC recommendations

Easy 4 step process from sample entry to results. No laboratory training required.

Clinical Significance

The Viral Respiratory Tract Infections (VRI) test offers a rapid and comprehensive solution, capable of detecting 10 different viral respiratory infections, including SARS-CoV-2, within a remarkably short timeframe of 2 hours and 30 minutes.

This extensive panel equips healthcare providers with the ability to swiftly identify potential co-infections, thereby enabling them to make more informed treatment decisions for patients grappling with respiratory illnesses. The expedited detection of multiple viruses not only aids in timely intervention but also holds the promise of reducing unnecessary antibiotic usage, consequently leading to improved patient outcomes and more effective management of respiratory conditions.

Features

Sample Type: Nasopharyngeal or Oropharyngeal Swab (eNAT)

Sample Volume: 300 μl

Detection Method: Randox Biochip Technology (end-point PCR)

Time to result: 2 hours 30 minutes

Detectable Viruses
SARS-CoV-2 (COVID-19)	Sarbecovirus (SARS, SARS like, SARS-CoV-2)	Influenza A
Coronavirus 229E/NL63	Adenovirus A/B/C/D/E	Influenza B
Coronavirus OC43/HKUI	Enterovirus A/B/C/D / Rhinovirus A/B/C	Respiratory Syncytial Virus A/B (RSV)
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)	Adenovirus A/B/C/D/E

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

Want to know more?

COVID-19 Management & Monitoring

Related Products

SARS-CoV-2 Rapid Test

SARS-CoV-2 Pooling Test

Vivalytic

Vivalytic Test Menu

Norbrook partners with Randox on staff screening programme for COVID-19

Posted on 27th May 2020 at 12:13 pm.

Written by Randox Communications

News About Us COVID-19

27 May 2020

Norbrook partners with Randox on staff screening programme for COVID-19

Pharmaceuticals company Norbrook Laboratories has revealed that it will be the first company in Northern Ireland to install an innovative COVID-19 testing platform for on-site staff screening.

The Newry-based firm, which specialises in the development of pharmaceuticals for the veterinary industry, will begin testing for its workforce in the coming weeks, to provide reassurance and peace of mind for colleagues and for their families, without impacting on the public health need.

The COVID-19 screening programme at Norbrook is being facilitated by diagnostic technology from global diagnostics company Randox, one of the partners within the national COVID-19 testing programme.

David Ferguson, Managing Director at Randox Food Diagnostics explained;

“Collectively we are all working towards a timely return to a more normal society, which will see companies reopening and people returning to work.

“To facilitate this recovery of the economy, without compromising the health of workers or of the wider general public, workplaces have a responsibility to provide a safe working environment.

“We know that the health of Norbrook’s staff is their priority and as such it is great to see them taking a proactive approach to testing.”

The COVID-19 screening programme at Norbrook is the first in Northern Ireland being facilitated by an innovative testing platform capable of processing results in 2hours 30 mins.

The technology, named the Vivalytic, can screen for SARS-CoV-2, the virus that causes COVID-19, as well as a range of other viral and bacterial infections including Influenza A and B, Pneumonia and other coronaviruses.

David added;

“Randox is fully committed to supporting the national effort to fight COVID-19 by testing at scale, and as we continue to work alongside the government and ramp up our testing capabilities, we welcome the fact that other organisations are also adopting our innovative COVID-19 testing technologies to address their own particular testing needs.

“The Vivalytic, which provides high quality molecular testing for COVID-19, on-site and without the need for laboratory experience, is a unique space-saving, hygienic solution for personnel COVID-19 testing in any setting and will help a wide variety of industries get back to business by ensuring the highest level of safety.”

Denise Collins, Norbrook Human Resources Director, concluded;

“We’re proud to be working with a company like Randox which has such vast experience in the diagnostics industry and was subsequently able to respond so quickly to the COVID-19 pandemic.

“That this world-leading technology is available from a Northern Ireland-headquartered company presents a unique opportunity for workplaces here to quickly and easily implement a staff screening programme, and at the same time demonstrate a high standard of duty of care that should be shown by employers to their employees.”

For further information about the Vivalytic please email marketing@randox.com

Want to know more about Randox?

Our Randox Products and Services

REAGENTS

RX SERIES

ACUSERA

BIOCHIP

Point of care coronavirus test from Randox and Bosch will launch in April 2020

Posted on 26th March 2020 at 1:33 pm.

Written by Randox Communications

26 March 2020

Vivalytic Viral Respiratory Tract Infection Array Detecting SARS-CoV-2 (COVID-19)

A game-changing point of care coronavirus test from global diagnostics company Randox Laboratories and leading technology manufacturer Bosch Healthcare Solutions will launch in April 2020.

The Vivalytic Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.

This provides a more comprehensive respiratory screening which enables precise and informed treatment decisions to be made.

Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences, commented;

“This array focuses not only on the identification of the novel coronavirus strain that causes COVID-19, but also nine other respiratory infection targets simultaneously, including Influenza A and B, Sarbecovirus and MERS. The aim is to diagnose patients fast and accurately from a single genetic sample, maximising containment of the virus whilst minimising the spread. With the development of this array onto a fully automated platform, patients can be diagnosed rapidly at point of care locations globally such as pharmacies and doctor surgeries.”

The Viral Respiratory Tract Infection Array is one of the world’s first multiplex molecular diagnostic tests meeting the COVID-19 testing recommendations of the World Health Organisation (WHO) and the Centres for Disease Control (CDC).

The target genes for COVID-19 being used on the VRI array represent conserved regions of the genome which have been chosen for their high sensitivity and specificity.

Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said:

“We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”

The new VRI test will be conducted on Vivalytic a point of care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The cartridges are fully-sealed which minimises the risk of contamination, require room temperature storage (space-saving), contain all the reagents on-board the cartridge and utilises end point PCR. The test only requires a single nasal swab from the patient and an easy four step process to be carried out by the user to run the patient sample.

Key Benefits of Vivalytic | Point of Care Platform

Fully-automated
User friendly
No laboratory training required
4 step work flow
Minimal contamination risk – fully contained system
No peripherals required – hygienic
Touchscreen
Connects to LIMS (Laboratory Information Management System)
Sample Type: Nasopharyngeal Swab
Sample Volume: 300µl clinical sample

For more information or to arrange interviews, please contact info@randoxbiosciences.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS

Multiplex STI assay for 10 sexually transmitted infections receives CE marking

Posted on 2nd March 2020 at 3:31 pm.

Written by Randox Communications

02 March 2020

Multiplex assay for 10 sexually transmitted infections receives CE marking

CE marking has been granted to one of the most comprehensive cartridge-based STI tests.

The test, developed by the UK’s largest health diagnostics company, Randox Laboratories, tests simultaneously for 10 of the most common sexually transmitted infections, on the firm’s patented Biochip Technology.

Quickly and efficiently testing for multiple STIs, which often have mild symptoms if any at all, ensures early diagnosis at a stage when treatment is most successful, supports the targeted use of antibiotics, and ultimately reduces their mishandling.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

“Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. The CE marking of the STI assay, which incorporates Randox Biochip Technology, will be a game-changer for clinicians and patients across Europe, by facilitating early, accurate and comprehensive diagnoses of STIs that allows for the best possible patient outcome. Never before has there been this level of accessibility and speed with regards to STI testing.”

The Randox STI assay is performed on the Vivalytic system, an intuitive point-of-care platform, developed in partnership with German technology company Bosch that provides the broadest range of test options ever seen for an analyser of its size.

Harnessing the application of multiplex assays to provide greater information from a single patient sample, the Vivalytic simplifies the testing process for otherwise complex laboratory testing procedures.

Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said:

Benefits of the Randox STI assay technology on the Vivalytic system

Fully automated, cartridge-based molecular diagnostics.
Multiplex technology detects multiple STIs, including co-infections, from a single patient sample.
Full molecular workflow of extraction, PCR amplification and detection.
A hygiene and space-saving all-in-one solution that does not require additional peripherals such as laptop, keyboard, barcode scanner or filling stations.
Ultimate protection of data and valuable sample material thanks to integration of software with instrument that ensures a safe and reliable run.
Test results can be presented either in summary or in detailed raw data form.
Instantly available results due to easy integration with popular standard IT systems.

The assay tests simultaneously, from one patient sample, for the STIs below;

Chlamydia trachomatis (CT)
Neisseria Gonorrhoeae (NG)
Trichomonas vaginalis (TV)
Mycoplasma genitalium (MG)
Treponema pallidum (syphilis) (TP)
Herpes simplex virus 1 (HSV-1)
Herpes simplex virus 2 (HSV-2)
Haemophilus ducreyl (HD)
Mycoplasma hominis (MH)
Ureaplasma urealyticum (UU)

For further information please contact the Randox PR team on 028 9442 2413 or email randoxpr@randox.com

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS

Randox actively testing samples for Coronavirus COVID-19

Posted on 12th February 2020 at 12:01 am.

Written by Randox Communications

12 February 2020

Introducing the COVID-19 Coronavirus Test from Randox

A ground-breaking test for the potentially fatal COVID-19 strain of coronavirus, is available at global health diagnostics company Randox Laboratories.

The test, developed on Randox’s patented Biochip Technology, is as an enhanced multiplex array which includes tests for COVID-19 and nine other respiratory viruses which can display the same symptoms.

The new enhanced Biochip therefore allows clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

“Current technologies for the diagnosis of coronavirus are designed simply to detect the presence or lack of COVID-19, and therefore neglect to differentiate between this strain and other respiratory infections.

“We have therefore developed an extended Viral Respiratory Infection Array that tests simultaneously for COVID-19 and nine other viruses. This will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found, and empower clinicians to make fast and informed decisions.”

The test is available on the Randox Evidence Investigator with a turnaround time of 5 hours.

Benefits of the new Randox COVID-19 test

Quick Turnaround Times (5 hours on Evidence Investigator)
Multiplex array differentiates between mild and serious infection
Automated and Semi-Automated options available
Medium to high throughput (54 samples in 5 hours)

For further information please visit www.randox.com/coronavirus-randox

QNOSTICS

QCMD

BIOSCIENCES

Coronavirus test available at Randox

Posted on 26th January 2020 at 12:01 am.

Written by Randox Communications

26 January 2020

Introducing the COVID-19 Coronavirus Test from Randox

A ground-breaking test for the potentially fatal COVID-19 strain of coronavirus, is in the final stages of development at global health diagnostics company Randox Laboratories.

The soon-to-be-launched test, developed on Randox’s patented Biochip Technology, will be available for immediate COVID-19 testing, but an additional enhanced multiplex array will also include tests for other respiratory viruses which can display the same symptoms.

The new enhanced Biochip will therefore allow clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections.

Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

“Whilst we’re very quickly developing an efficient novel test for this new strain of coronavirus, we are therefore also working on an extended Viral Respiratory Infection Array that will test simultaneously for COVID-19 and a range of other viruses. This will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found, and empower clinicians to make fast and informed decisions.”

The test will be available for the Point of Care analyser, the Vivalytic, within 3 hours, and within 5 hours on the Randox Evidence Investigator.

Benefits of the new Randox COVID-19 test

Quick Turnaround Times (3 hours on Vivalytic and 5 hours on Evidence Investigator)
Multiplex array differentiates between mild and serious infection
Automated and Semi-Automated options available

Randox also currently has available a Respiratory Tract Infection Array, which can test for 22 viral and bacterial respiratory infections simultaneously. The test therefore determines the exact cause of your symptoms and differentiates between mild and serious infections, such as coronavirus. This is also available from Randox Health as a Cold, Cough and Flu test.

For further information please visit www.randox.com/coronavirus-randox

For enquiries email marketing@randox.com or to book your Randox Health Cough, Cold and Flu test please ring 0800 2545 130.

Randox is committed to saving and improving lives on a global scale, and will bring you updates on developments on our test for COVID-19 as and when they happen.

QNOSTICS

QCMD

BIOSCIENCES

Vivalytic Powered by Randox Biochip Technology: Upper and Lower Respiratory Tract Testing

Posted on 15th November 2019 at 12:01 am.

Written by Randox Communications

15 November 2019

Vivalytic Powered by Randox Biochip Technology: Upper and Lower Respiratory Tract Testing

Vivalytic will revolutionise the way laboratories and healthcare professionals access molecular diagnostics. A result of a collaboration between Bosch – providing innovative strength – and Randox Laboratories – dedicated to improving global healthcare – Vivalytic is the new innovative testing platform. It’s the perfect fit for any laboratory, with numerous benefits to enhance testing capabilities.

The Vivalytic is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. Vivalytic cartridges are compact, utilising micro-fluidics to enable simple and accurate diagnostic testing. Hi-Plex tests utilise Randox patented Biochip Technology, enabling end-point qualitative PCR and providing multiple test results from each sample. Lo-Plex tests are based on a variety of detection methods including real-time qualitative PCR and melting curve analysis. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required.

Vivalytic is the perfect fit for a healthcare professional in a point of care setting to a laboratory, which can implement the Vivalytic Up – modular and expandable testing system for higher throughput.

Benefits include:

Fully Automated Platform
Protected System
Direct and Clear Results
Hygienic and Space Saving

Vivalytic Test Menu

Vivalytic offers the most comprehensive multiplex screening test for infectious diseases including respiratory, genitourinary and hospital acquired infections; simultaneously detecting both viral and bacterial infections (please see figure 1.).

Respiratory Tract Infection Array		Sexually Transmitted Infection Array	Hospital Acquired Infections
Bacterial	Viral
Bordetella Pertussis	Influenza A	Chlamydia trachomatis (CT)	Methicillin-resistant Staphylococcus aureus (MRSA)
Chlamydophila pneumoniae	Influenza B	Ureaplasma urealyticum (UU)	Methicillin-sensitive Staphylococcus aureus (MSSA)
Haemophilus influenzae	Human adenovirus A/B/C/D/E	Neisseria gonorrhoea (NG)	Methicillin-resistant coagulase-negative Staphylococci (MRCoNS)
Legionella pneumophila	Human bocavirus 1/2/3	Mycoplasma genitalium (MG)
Moraxella catarrhalis	Human coronavirus 229E/NL63	Trichomonas vaginalis (TV)
Mycoplasma pneumoniae	Human coronavirus OC43/HKU1	Haemophilus ducreyi (HD)
Streptococcus pneumoniae	Human enterovirus A/B/C	Mycoplasma hominis (MH)
Bordetella parapertussis	Human Metapneumovirus	Treponema pallidum (TP)
	Human parainfluenza virus 1	Herpes simplex Virus 1 (HSV-1)
	Human parainfluenza virus 2	Herpes simplex Virus 2 (HSV-2)
	Human parainfluenza virus 3
	Human parainfluenza virus 4
	Human respiratory syncytial virus A & B
	Human rhinovirus A/B/C

Figure 1.

Lower and Upper Respiratory Tract Infections

The economic burden of respiratory illness in the UK costs a staggering £11 billion every year on lung disease alone¹. Lower respiratory tract infections (LRIs) are a substantial public health problem and a leading cause of illness and death in people of all ages^2. It is estimated that LRI causes nearly 4 million deaths annually³. Upper respiratory tract infections (URIs) account for an estimated 10 million outpatient appointments a year. Most of these appointments end with physicians needless writing of antibiotic prescriptions⁴.

Randox Biosciences offers a Respiratory Multiplex Array which rapidly detects and identifies the cause of 22 bacterial and viral pathogens helping to reduce the risk of antibiotic resistance. Given that only bacterial infections can be treated with antibiotics, rapid diagnostic tests are urgently needed to distinguish between bacterial and viral infections. This test will aid clinicians in their selection of the most appropriate antibiotic treatment for patients. GPs would have additional efficiency savings for the NHS, by eliminating the need for lengthy microbiology lab tests and unnecessarily writing prescriptions.

The test is performed utilising our Biochip Technology which enables the simultaneous detection of multiple results from one patient sample. Biochip Technology powers Vivalytic which is the all-one solution for molecular diagnostics.

The main benefits of the Respiratory Multiplex Array are:

Turnaround time of 2 hours
Validated for sputum, lavage and nasopharyngeal samples
Panel includes viral and bacterial species to consolidate testing

Randox Biosciences are committed to the ongoing development of diagnostic tests, through our research into numerous disease areas, to improve health worldwide.

MEDICA World Forum for Medicine International Trade Fair

Randox Biosciences team will be attending Medica from the 18^th – 21^st of November 2019 at Messe Dusseldorf, Germany. Stop by and say hello to some of our team members at our stand, and to learn more about our latest game-changing partnership with Bosch – the innovative Vivalytic platform!

Medica is at the forefront of new approaches in laboratory medicine, addressing the complexity of an evolving healthcare landscape. This event attracts more than 5,100 exhibitors from 70 countries, engaging diverse professionals enabling them to discover new and innovative solutions to improving patient outcomes through effective lab testing, diagnosis and treatment.

To learn more about the Vivalytic offering, visit https://www.randoxbiosciences.com/clinical-laboratory/infectious-diseases/molecular-arrays/ or email us at info@randoxbiosciences.com

References:

British Lung Foundation. (2019). Estimating the economic burden of respiratory illness in the UK. [online] Available at https://www.blf.org.uk/policy/economic-burden [Accessed 06 Nov. 2019].
The Lancet Infectious Diseases. (2015). Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. [online] Available at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30396-1/fulltext [Accessed 29 Oct. 2019].
Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017.
Thomas, M. and Bomar, P. The National Centre for Biotechnology. Upper Respiratory Tract Infection. United States of America.

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS